Bausch & Lomb CORP 10-Q quarterly reports

Bausch + Lomb Corporation announced a significant increase in revenues and operating income for the second quarter of 2026, driven by strong performance across its Vision Care, Pharmaceuticals, and Surgical segments.

Bausch + Lomb Corporation announced its first quarter 2026 financial results, reporting a 9% increase in total revenues to $1.244 billion, driven by favorable foreign currency impacts, increased pricing, and higher volumes across key segments.

Bausch + Lomb reported a 7% increase in Q3 revenues to $1.28 billion, but net loss widened to $28 million, impacted by higher expenses and a voluntary IOL recall.

Bausch + Lomb announced a 5% increase in second-quarter revenues to $1.278 billion, driven by volume growth and acquisitions, despite an operating loss of $11 million and increased interest expenses following a significant debt refinancing.

Bausch + Lomb saw a revenue increase in Q1 2025, but a voluntary recall and increased expenses led to a larger net loss compared to the same period last year.

Bausch + Lomb's Q3 2024 results show a significant revenue increase driven by recent acquisitions and higher sales volumes across its segments.

Bausch + Lomb's second quarter 2024 results show a significant revenue increase driven by acquisitions and volume growth, though net losses persist.

Bausch + Lomb's first quarter 2024 results show a significant revenue increase of 18% compared to the same period last year, driven by acquisitions and volume growth.